|Bid||3.2200 x 800|
|Ask||3.2400 x 1100|
|Day's Range||3.1000 - 3.3500|
|52 Week Range||2.3500 - 62.0000|
|Beta (5Y Monthly)||2.64|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.00|
Investors sold off shares of the biopharmaceutical company after it reported negative results from a phase 3 clinical trial. BiondVax Pharmaceuticals is developing a potential stand-alone universal flu vaccine, M-001. In a pivotal clinical trial, the company tested M-001's safety and efficacy at reducing flu illness and severity.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, future, seasonal and pandemic influenza, today announced topline data from the Company's pivotal, phase 3 clinical trial of M-001 as a standalone universal flu vaccine candidate.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the Phase 3 clinical trial M–001 universal influenza vaccine candidate ("BiondVax" or the "Company"), today announced it has entered into an agreement with BofA Securities as lead sales agent, and Citigroup and Credit Suisse as participating sales agents (collectively, the "Agents"), related to a $100 million At-The-Market (the "ATM Program") equity offering program pursuant to a prospectus supplement filed today with the Securities and Exchange Commission (the "SEC").